H.I.G. BioHealth closes $220 mln HyperBranch Medical sale
Summary
Capital, said Oct. 11 that closed the sale of it HyperBranch Medical Technology Inc to Stryker Corp for about $220 million.HyperBranch is dedicated to developing medical devices based on its proprietary polymers and cross-linked hydrogels.Managing Director and former HyperBranch board member, said, “Together with HyperBranch’s talented management team and board, we successfully grew the company into a leader in the surgical sealant space, commercializing innovative products with significant benefits to patients, physicians and healthcare providers.”Buyouts delivers exclusive news and analysis about private equity deals, fundraising, top-quartile managers and more.VC Journal provides exclusive news and analysis about venture capital deals, fundraising, top-quartile investors and more.